AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39743016 — intervention group
Group type: EXPERIMENTAL
Intervention: InBloom app (asynchronously delivered intervention)
Number of subjects: 152
Study 39743016 — intervention group
Group type: COMPARATOR
Intervention: ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) intervention (synchronously delivered in-person intervention)
Number of subjects: 152
Study 39743016 — intervention group
Group type: COMPARATOR
Intervention: Historical control subjects from the largest ROSE trial
Number of subjects: 152
Study 39743016 — intervention group
Group type: COMPARATOR
Intervention: Electronic Health Record (EHR) data on concurrent patients not offered InBloom or ROSE
Number of subjects: 152
Study 39743172 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (BB)
Number of subjects: 200
Study 39743172 — intervention group
Group type: COMPARATOR
Intervention: No beta-blockers (no BB)
Number of subjects: 200
Study 39743240 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming
Number of subjects: 104
Study 39743240 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical yoga
Number of subjects: 104
Study 39743240 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 39743326 — intervention group
Group type: EXPERIMENTAL
Intervention: EOLD-CAD scale
Number of subjects: 611
Study 39743436 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10, 20, or 25 mg/kg) administered intravenously on Days 1, 5±2, and 14±2
Number of subjects: 21
Study 39743436 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10, 20, or 25 mg/kg) with concomitant ruxolitinib and corticosteroids
Number of subjects: 21
Study 39743478 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line oxaliplatin-based chemotherapy
Number of subjects: 40
Study 39743618 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-L1 blockade Adebrelimab (two cycles)
Number of subjects: 23
Study 39744036 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS and hedonic olfactory stimulations
Number of subjects: 80
Study 39744036 — intervention group
Group type: COMPARATOR
Intervention: rTMS alone
Number of subjects: 80
Study 39744082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pair condition (participants with a partner)
Number of subjects: 125
Study 39744082 — intervention group
Group type: EXPERIMENTAL
Intervention: Alone condition (participants alone)
Number of subjects: 125
Study 39744082 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls) in Pair condition
Number of subjects: 125
Study 39744206 — intervention group
Group type: EXPERIMENTAL
Intervention: 16s ribosomal RNA PCR
Number of subjects: 100
Study 39744206 — intervention group
Group type: COMPARATOR
Intervention: Valve culture
Number of subjects: 100
Study 39744206 — intervention group
Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 100
Study 39744206 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular test combined with histopathological analysis
Number of subjects: 100
Study 39744206 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular test
Number of subjects: 100
Study 39744353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1830
Study 39744353 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1830
Study 39744353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1830
Study 39744679 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39744745 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 3 ml 0.1% ropivacaine with 0.3 μg ml-1 sufentanil through the Tuohy needle followed by a 15 ml loading dose over 30 seconds
Number of subjects: 200
Study 39744745 — intervention group
Group type: COMPARATOR
Intervention: Injection of the same ropivacaine/sufentanil mixture through a single end-hole epidural catheter
Number of subjects: 200
Study 39744837 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 352
Study 39744837 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 352
Study 39744861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg intravenously)
Number of subjects: 224
Study 39744861 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (including 23% receiving intravenous tissue-type plasminogen activator)
Number of subjects: 224
Study 39744861 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 224
Study 39744866 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated silicone transurethral indwelling catheters (TICs)
Number of subjects: 310
Study 39744866 — intervention group
Group type: COMPARATOR
Intervention: Standard silicone transurethral indwelling catheters (TICs)
Number of subjects: 310
Study 39744921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 μg orally twice daily for 48 weeks
Number of subjects: 116
Study 39744921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 39744963 — intervention group
Group type: COMPARATOR
Intervention: PRPP Intervention (9 sessions)
Number of subjects: 3
Study 39745099 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT) intervention
Number of subjects: 84
Study 39745099 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 84
Study 39745099 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical assessments after 6 months of cancer treatment
Number of subjects: 84
Study 39745261 — intervention group
Group type: EXPERIMENTAL
Intervention: Adeno-Associated Virus Vector Serotype 2-Mediated Gene Therapy to the Central Nervous System
Number of subjects: 0
Study 39745289 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 158
Study 39745289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 39745404 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SBP categories (<120, 120-129, 130-139, and ≥140 mm Hg)
Number of subjects: 16950
Study 39745404 — intervention group
Group type: EXPERIMENTAL
Intervention: PP quartiles (reference: 46-54 mm Hg)
Number of subjects: 16950
Study 39745404 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous baseline SBP and PP
Number of subjects: 16950
Study 39745404 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PP
Number of subjects: 16950
Study 39745520 — intervention group
Group type: EXPERIMENTAL
Intervention: With a chaperone during proctological exam
Number of subjects: 190
Study 39745520 — intervention group
Group type: COMPARATOR
Intervention: Without a chaperone during proctological exam
Number of subjects: 190
Study 39745526 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel PSMA-targeting radiopharmaceutical
Number of subjects: 0
Study 39745672 — intervention group
Group type: EXPERIMENTAL
Intervention: BBTI training alone
Number of subjects: 0
Study 39745672 — intervention group
Group type: EXPERIMENTAL
Intervention: BBTI + IS (training plus implementation strategies)
Number of subjects: 0
Study 39745672 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39745682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontransplant salvage therapy (radiotherapy) for low-risk patients (n=41)
Number of subjects: 118
Study 39745682 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCT/aSCT off protocol for low-risk patients (n=18)
Number of subjects: 118
Study 39745682 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCT/aSCT for high-risk patients (n=59)
Number of subjects: 118
Study 39745701 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-targeted oral health text (OHT) messages
Number of subjects: 754
Study 39745701 — intervention group
Group type: COMPARATOR
Intervention: Child wellness text (CWT) messages
Number of subjects: 754
Study 39745702 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant quadrivalent influenza vaccine (RIV4)
Number of subjects: 144565
Study 39745702 — intervention group
Group type: COMPARATOR
Intervention: Standard egg-based quadrivalent inactivated influenza vaccine (IIV4)
Number of subjects: 144565
Study 39745739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response and involved-site radiotherapy (ISRT) at 30.0 to 30.6 Gy.
Number of subjects: 28
Study 39746099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal temperature measurement using ETT thermometer
Number of subjects: 11
Study 39746099 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery catheter (PAC) temperature measurement
Number of subjects: 11
Study 39746186 — intervention group
Group type: EXPERIMENTAL
Intervention: HPI-guided management
Number of subjects: 917
Study 39746186 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 917
Study 39746206 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF
Number of subjects: 7386
Study 39746206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7386
Study 39746210 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus meditation and yoga (mind-body group)
Number of subjects: 97
Study 39746210 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (control group)
Number of subjects: 97
Study 39746212 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF 120 micrograms
Number of subjects: 7420
Study 39746212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7420
Study 39746387 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography guided (EC)-LBBP
Number of subjects: 30
Study 39746387 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 30
Study 39746473 — intervention group
Group type: EXPERIMENTAL
Intervention: cQFR <0.875
Number of subjects: 1931
Study 39746473 — intervention group
Group type: COMPARATOR
Intervention: cQFR ≥0.875
Number of subjects: 1931
Study 39746473 — intervention group
Group type: EXPERIMENTAL
Intervention: cQFR
Number of subjects: 1931
Study 39746515 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB)
Number of subjects: 0
Study 39746515 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB) combined with mometasone furoate nasal spray (MFNS)
Number of subjects: 0
Study 39746515 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 0
Study 39746883 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision coaching intervention
Number of subjects: 8
Study 39746883 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional Conflict Scale
Number of subjects: 8
Study 39746883 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 8
Study 39746964 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan (HE072) at dose levels of 50, 70, and 90 mg/m²
Number of subjects: 0
Study 39747123 — intervention group
Group type: EXPERIMENTAL
Intervention: C5/MCD subtype, i/eot-PET-negative status
Number of subjects: 592
Study 39747123 — intervention group
Group type: EXPERIMENTAL
Intervention: C2/A53 subtype, i/eot-PET-negative status
Number of subjects: 592
Study 39747123 — intervention group
Group type: EXPERIMENTAL
Intervention: Other subtypes (not C5/MCD or C2/A53), i/eot-PET-negative status
Number of subjects: 592
Study 39747123 — intervention group
Group type: EXPERIMENTAL
Intervention: i/eot-PET-positive status for all subtypes
Number of subjects: 592
Study 39747123 — intervention group
Group type: EXPERIMENTAL
Intervention: C5 i/eot-PET-negative patients
Number of subjects: 592
Study 39747681 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 53
Study 39747681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 39747856 — intervention group
Group type: EXPERIMENTAL
Intervention: GT103 (0.3 mg/kg)
Number of subjects: 31
Study 39747856 — intervention group
Group type: EXPERIMENTAL
Intervention: GT103 (1 mg/kg)
Number of subjects: 31
Study 39747856 — intervention group
Group type: EXPERIMENTAL
Intervention: GT103 (10 mg/kg every 3 weeks)
Number of subjects: 31
Study 39747856 — intervention group
Group type: EXPERIMENTAL
Intervention: GT103 (various doses)
Number of subjects: 31
Study 39747856 — intervention group
Group type: EXPERIMENTAL
Intervention: GT103
Number of subjects: 31
Study 39747932 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT targeting prostate-specific membrane antigen (PSMA)
Number of subjects: 0
Study 39747998 — intervention group
Group type: EXPERIMENTAL
Intervention: Delandistrogene moxeparvovec micro-dystrophin gene therapy
Number of subjects: 0
Study 39747998 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma ELISpot assay
Number of subjects: 0
Study 39747998 — intervention group
Group type: EXPERIMENTAL
Intervention: In silico epitope mapping
Number of subjects: 0
Study 39748155 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine-based regimen (DOR/lamivudine/TDF)
Number of subjects: 502
Study 39748155 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine-based regimen (DOR + 2 NRTIs)
Number of subjects: 502
Study 39748155 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine-based regimen (DOR)
Number of subjects: 502
Study 39748312 — intervention group
Group type: EXPERIMENTAL
Intervention: Zavegepant 10 mg nasal spray
Number of subjects: 1269
Study 39748312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1269
Study 39748327 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for preterm birth (PTB) based on psychosocial predictors including being unmarried, social support score, intimate partner violence (IPV), and mild-to-severe depressive symptoms (CESD-10 score ≥ 5).
Number of subjects: 4084
Study 39748327 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of PTB including being unmarried, lower education, IPV (HITS score ≥ 5), higher CESD-10 score, lower social support score, and mild-to-severe depressive symptoms.
Number of subjects: 4084
Study 39748361 — intervention group
Group type: EXPERIMENTAL
Intervention: Finnish Diabetes Risk Score (FINDRISC) assessment
Number of subjects: 100
Study 39748361 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index-2015 (HEI-2015) dietary assessment
Number of subjects: 100
Study 39748361 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model analysis
Number of subjects: 100
Study 39748396 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal breastmilk expression (aBME) for 10 minutes, 2 times daily from week 34 until birth.
Number of subjects: 60
Study 39748396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aBME).
Number of subjects: 60
Study 39748396 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal breastmilk expression (aBME).
Number of subjects: 60
Study 39748428 — intervention group
Group type: EXPERIMENTAL
Intervention: CD33-targeted CAR-NK cell therapy
Number of subjects: 10
Study 39748491 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal mitoxantrone (Lipo-MIT) monotherapy
Number of subjects: 108
Study 39748503 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interview-based training program (6 sessions)
Number of subjects: 76
Study 39748503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 76
Study 39748512 — intervention group
Group type: EXPERIMENTAL
Intervention: Panorama algorithm (context-aware autoscoring)
Number of subjects: 266
Study 39748512 — intervention group
Group type: COMPARATOR
Intervention: Conventional context-unaware algorithm
Number of subjects: 266
Study 39748640 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body magnetic resonance imaging (WBM) and multicancer early detection (MCED) testing
Number of subjects: 100
Study 39748726 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 FF-21101 (25 mCi/m)
Number of subjects: 57
Study 39749040 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tumors group
Number of subjects: 0
Study 39749040 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive lacunar stroke (LS) group
Number of subjects: 0
Study 39749040 — intervention group
Group type: COMPARATOR
Intervention: Inactive tumors group
Number of subjects: 0
Study 39749040 — intervention group
Group type: COMPARATOR
Intervention: Non-hypertensive embolic stroke (NHES) group
Number of subjects: 0
Study 39749255 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Cardiorespiratory Fitness (CRF)
Number of subjects: 0
Study 39749328 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-ST (prefusion-stabilized spike protein)
Number of subjects: 0
Study 39749328 — intervention group
Group type: COMPARATOR
Intervention: MVA-SARS-2-S (native spike protein)
Number of subjects: 0
Study 39749328 — intervention group
Group type: COMPARATOR
Intervention: ChAd vaccine
Number of subjects: 0
Study 39749328 — intervention group
Group type: COMPARATOR
Intervention: mRNA vaccine
Number of subjects: 0
Study 39749486 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses during childbirth
Number of subjects: 60
Study 39749486 — intervention group
Group type: COMPARATOR
Intervention: Control group (no virtual reality intervention)
Number of subjects: 60
Study 39749517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rainbow 5-plex proviral HIV-1 DNA assay
Number of subjects: 83
Study 39749517 — intervention group
Group type: COMPARATOR
Intervention: IPDA
Number of subjects: 83
Study 39749517 — intervention group
Group type: COMPARATOR
Intervention: Q4PCR
Number of subjects: 83
Study 39749555 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF with corticosteroid injection
Number of subjects: 400
Study 39749555 — intervention group
Group type: COMPARATOR
Intervention: PNF with saline injection
Number of subjects: 400
Study 39749571 — intervention group
Group type: EXPERIMENTAL
Intervention: WNT5a
Number of subjects: 0
Study 39749571 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-β
Number of subjects: 0
Study 39749650 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE ε4 carriers
Number of subjects: 575
Study 39749650 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE ε4+ AD groups
Number of subjects: 575
Study 39749650 — intervention group
Group type: COMPARATOR
Intervention: AD group
Number of subjects: 575
Study 39749650 — intervention group
Group type: COMPARATOR
Intervention: non-AD dementia group
Number of subjects: 575
Study 39749727 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 2-4 mg/day
Number of subjects: 1000
Study 39749727 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1000
Study 39749912 — intervention group
Group type: EXPERIMENTAL
Intervention: Early routine left ventricular unloading by transseptal left atrial cannulation within 12 hours after randomization
Number of subjects: 116
Study 39749912 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach permitting rescue transseptal cannulation
Number of subjects: 116
Study 39749912 — intervention group
Group type: EXPERIMENTAL
Intervention: Early routine left ventricular unloading
Number of subjects: 116
Study 39749912 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 116
Study 39751879 — intervention group
Group type: EXPERIMENTAL
Intervention: Serplulimab 3 mg/kg plus HLX04 10 mg/kg (first-line)
Number of subjects: 61
Study 39751937 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 blockade-activated neoantigen specific cellular therapy (aNASCT)
Number of subjects: 13
Study 39751962 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant darolutamide plus androgen deprivation therapy (ADT) for six months
Number of subjects: 30
Study 39751962 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant darolutamide plus ADT for six months
Number of subjects: 30
Study 39751970 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine-butorphanol group (Group BK) receiving esketamine 1.5 mg/kg and butorphanol 0.15 mg/kg, azasetron 20 mg.
Number of subjects: 181
Study 39751970 — intervention group
Group type: COMPARATOR
Intervention: Butorphanol group (Group B) receiving butorphanol 0.15 mg/kg and azasetron 20 mg (normal saline as control).
Number of subjects: 181
Study 39751970 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine-butorphanol group (Group BK).
Number of subjects: 181
Study 39751989 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail patients with Parkinson's disease
Number of subjects: 90
Study 39751989 — intervention group
Group type: COMPARATOR
Intervention: Pre-frail and robust patients
Number of subjects: 90
Study 39752160 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruptive CDS
Number of subjects: 561
Study 39752160 — intervention group
Group type: COMPARATOR
Intervention: Noninterruptive CDS
Number of subjects: 561
Study 39752160 — intervention group
Group type: COMPARATOR
Intervention: Baseline rate
Number of subjects: 561
Study 39752160 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 561
Study 39752191 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day multimodal intensive educational intervention (supervision-based online teaching)
Number of subjects: 160
Study 39752191 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention during this period)
Number of subjects: 160
Study 39752236 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney Stone Disease management in ADPKD patients
Number of subjects: 0
Study 39752249 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized breathing with cardiac biofeedback (BFB)
Number of subjects: 482
Study 39752249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 482
Study 39752249 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (PPI)
Number of subjects: 482
Study 39752249 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 482
Study 39752329 — intervention group
Group type: EXPERIMENTAL
Intervention: PsAID12 score <1.7
Number of subjects: 410
Study 39752329 — intervention group
Group type: EXPERIMENTAL
Intervention: PsAID12 score ≥1.7 to ≤3.1
Number of subjects: 410
Study 39752329 — intervention group
Group type: EXPERIMENTAL
Intervention: PsAID12 score >3.1 to <4.8
Number of subjects: 410
Study 39752329 — intervention group
Group type: EXPERIMENTAL
Intervention: PsAID12 score ≥4.8
Number of subjects: 410
Study 39752329 — intervention group
Group type: EXPERIMENTAL
Intervention: PsAID12 against DAPSA
Number of subjects: 410